Q-omics provides the consensus-scored CD164 profile across patient tissues and cancer cell-line models. CD164 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CD164 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, CD164 RNA expression shows 20,227 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KICH, and UVM as cancer lineages where CD164 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CD164 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CD164 survival associations across molecular data types. CD164 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CD164 RNA expression–survival associations across cancer types. High CD164 expression shows unfavorable associations in HNSC, LIHC, LGG and DLBC, but favorable associations in KIRC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CD164 RNA expression.
This table summarizes CD164 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CD164. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CD164 shows lower tumor expression in KICH, THCA, COAD and KIRC and higher tumor expression in HNSC and STAD. The KICH box plot shows higher CD164 RNA expression in normal versus tumor tissue (log2 FC = −1.849, t-test p < 0.001).
This table shows molecular features associated with CD164 in patient tissues and cancer cell lines. In patient samples, CD164 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CD164 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BONE and LUNG_SCLC.
